AVIR Q3 2025 Earnings — Atea Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AVIRAtea Pharmaceuticals, Inc.

$501M

Q3 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$46M

Net Income

-$42M

EPS (Diluted)

$-0.53

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$40M

Free Cash Flow

-$40M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$343M

Total Liabilities

$27M

Stockholders' Equity

$316M

Cash & Equivalents

$77M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	-$20M	+100.0%
Operating Income	-$46M	-$37M	-22.5%
Net Income	-$42M	-$31M	-35.0%